Alere (NYSE:ALR) is the #1 global provider of point of care testing. Abbott (NYSE:ABT) more broadly earns revenue from sales of nutritional supplements, medical devices, diagnostics and established pharmaceuticals. On February 1, it was announced that Abbott would acquire Alere for $56 per share in an all-cash transaction, resulting in a total enterprise value of $8.4 billion.
This is not a straightforward deal to analyze due to the fact that it is markedly dilutive on a GAAP basis and still dilutive on a non-GAAP basis (though management asserts it will be $0.12-$0.13/share accretive in 2017 and more than $0.20 accretive in 2018).
